PRESS RELEASES

31-Jul-2008	Amarin Announces Annual General Meeting Concluded
22-Jul-2008	Amarin Proceeding to Phase 3 with AMR101 for Hypertriglyceridemia
8-Jul-2008	Amarin Notice of Annual General Meeting
22-May-2008	Amarin announces completion of the first tranche of $60 million private placement. Appoints Four New Directors to Board.
19-May-2008	Amarin announces financial results for first quarter 2008
19-May-2008	Amarin announces financial results for fourth quarter and full year 2007
14-May-2008	Amarin announces private placement for up to $60 million
3-Mar-2008	Amarin Secures Global Intellectual Property Rights for Lipid Programs
11-Feb-2008	Amarin regains compliance with Nasdaq Listing Requirements
4-Feb-2008	Amarin appoints Dr. William Mason as Lead Independent Director
18-Jan-2008	Amarin provides business update and announces implementation of Reverse Stock Split
10-Jan-2008	Amarin to commence Phase II Trial with AMR101 in Age Associated Memory Impairment
9-Jan-2008	Amarin announces successful outcome of Nasal Lorazepam Study

Main Navigation